A precedent for this type of combination therapy approach includes the addition of ABL kinase inhibitors to standard chemotherapy regimens for children with Ph-positive ALL, which has dramatically improved clinical outcomes for these patients [17]. Here, ABL1 is linked to acute lymphoblastic leukemia.